326.84MMarket Cap
LossP/E TTM
Key Figures
1.220Open
1.235High
1.50MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.56%Turnover Ratio
1.220Prev. Close
1.200Low
1.42MTurnover
LossP/E Static
11.94P/B
0.00%Div Yield TTM
-6.10%ROA
4.07952wk High
0.75Volume Ratio
-69.41MNet Profit
267.90MShares
-0.0806EPS TTM
0.28Beta
-78.96%ROE
0.87552wk Low
2.87%Amplitude
69.75%Gross Margin
326.84MMarket Cap
1.93Reward/Risk
3.64%Risk Rate
Currency: USD Updated: 2026-07-24 Key Insights
Akebia Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 4.20.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Akebia Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Akebia Therapeutics Inc Highlights
StrengthsRisks
Akebia Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Akebia Therapeutics Inc
AKBA
5
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Akebia Therapeutics Inc Info
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Ticker SymbolAKBA
CompanyAkebia Therapeutics Inc
CEOButler (John P)
Websitehttps://akebia.com/
Shareholders
FAQs
What is the current price of Akebia Therapeutics Inc (AKBA)?
The current price of Akebia Therapeutics Inc (AKBA) is 1.22.
What is the symbol of Akebia Therapeutics Inc?
The ticker symbol of Akebia Therapeutics Inc is AKBA.
What is the 52-week high of Akebia Therapeutics Inc?
The 52-week high of Akebia Therapeutics Inc is 4.08.
What is the 52-week low of Akebia Therapeutics Inc?
The 52-week low of Akebia Therapeutics Inc is 0.88.
What is the market capitalization of Akebia Therapeutics Inc?
The market capitalization of Akebia Therapeutics Inc is 327.28M.
Is Akebia Therapeutics Inc (AKBA) currently rated as Buy, Hold, or Sell?
According to analysts, Akebia Therapeutics Inc (AKBA) has an overall rating of STRONG BUY, with a price target of 4.20.
What is the Earnings Per Share (EPS TTM) of Akebia Therapeutics Inc (AKBA)?
The Earnings Per Share (EPS TTM) of Akebia Therapeutics Inc (AKBA) is -0.02.
